AUTOIMMUNE DISEASE TIME TO DIAGNOSIS REDUCED IN PATIENTS WITH TYPE 2 DIABETES AND DELAYED WITH CONTINUOUS RAS THERAPY

Author(s)

Soto M, Bang SI, McCombs J, Rodgers K
University of Southern California, Los Angeles, CA, USA

OBJECTIVES: As the population of patients with type 2 diabetes (T2D) grows, it is important to look at the influence that it has on the onset of other disease. Autoimmune disease may be of particular interest because of the chronic low-grade inflammation in diabetic patients and connections to an imbalance in the Renin-Angiotensin System (RAS). This study aims to determine if RAS-modifying medications (angiotensin converting enzyme [ACE] inhibitors and angiotensin receptor blockers [ARBs]) have a beneficial impact on autoimmune disease in emerging T2D patients with hypertension (HTN) controlling for T2D and other factors. METHODS: A retrospective analysis was conducted using claims data from a US commercial insurance company (2007-2013). The study groups consisted of HTN patients taking either: ACE inhibitors, ARBs, or control (diuretics or calcium-channel blockers). Cox analyses were performed to determine the impact of ACE inhibitors and ARBs on incidence of autoimmune disease controlled for comorbidities, demographics, and diagnosis of T2D as a risk factor. Incidence and time to diagnosis were measured for multiple sclerosis [MS] (ICD-9 340.xx), systemic lupus erythematus [SLE] (ICD-9 710.0), and rheumatoid arthritis [RA] (ICD-9 714.xx). RESULTS: A total of 28,656 new T2D patients and 147,097 non-diabetic patients were identified. Patients with emerging T2D were not at increased risk for MS (HR 1.147, p=0.4384) or SLE (HR 1.254, p=0.0706) but were for RA (HR 1.299, p<.0001). There was however a significantly faster progression of the disease in all three autoimmune diseases in patients with T2D. RAS-modifying anti-hypertensives did not reduce incidence of disease but did delay disease onset with continued use. CONCLUSIONS: T2D has been shown to impact a variety of disease in incidence, severity, and onset; autoimmune disease may soon be included on this list. ACE inhibitors and ARBs may help delay the progression of MS, SLE and RA.

Conference/Value in Health Info

2017-05, ISPOR 2017, Boston, MA, USA

Value in Health, Vol. 20, No. 5 (May 2017)

Code

PDB20

Topic

Clinical Outcomes, Epidemiology & Public Health

Topic Subcategory

Comparative Effectiveness or Efficacy

Disease

Diabetes/Endocrine/Metabolic Disorders, Musculoskeletal Disorders, Neurological Disorders, Systemic Disorders/Conditions

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×